A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

NCT06773195 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ulixertinib
DRUG: Ruxolitinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]